MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

MetaVia (Nasdaq: MTVA) will present an update on its novel obesity and metabolic therapy pipeline at the Emerging Growth Conference on Wednesday, February 25, 2026 at 10:15 am ET.

Rhea-AI Summary

MetaVia (Nasdaq: MTVA) will present an update on its novel obesity and metabolic therapy pipeline at the Emerging Growth Conference on Wednesday, February 25, 2026 at 10:15 am ET. Management will include CEO Hyung Heon Kim and CFO Marshall H. Woodworth and will take audience questions after the talk.

Investors can register for the virtual conference, submit questions in advance to questions@emerginggrowth.com, or schedule one-on-one meetings via mmiller@rxir.com.

Argus Feb 17 session

-6.10% close to close 0.7x rel. volume Open Argus

Details

News Market Reaction – MTVA

On Feb 17, the day this news came out, MTVA closed 6.10% below the previous close.

Data tracked by StockTitan Argus for the Feb 17 session.

Key Figures

Conference date: February 25, 2026 Current price: $1.64 52-week range: $1.54–$23.10 +2 more

Conference date

February 25, 2026

Emerging Growth Conference presentation timing

Current price

$1.64

Pre-news trading level vs 52-week range

52-week range

$1.54–$23.10

Low and high over past 52 weeks

Volume spike

5.66x average

Today’s volume vs 20-day average

Market cap

$5,436,869

Equity value before conference update

Historical Context

5 past events · Latest: Feb 13

5 events

1. Feb 13

   IP protection update

   24h Move

   -1.2%

   Announced 39-patent portfolio for DA-1726 with protection into 2041.

2. Feb 04

   AI collaboration data

   24h Move

   -2.1%

   Reported positive AI-modeling results confirming targets for vanoglipel.

3. Jan 16

   Equity offering

   24h Move

   -3.5%

   Closed ~$9.3M underwritten public offering with Series C and D warrants.

4. Jan 05

   Phase 1b results

   24h Move

   -8.7%

   Reported statistically significant Phase 1b DA-1726 metabolic and weight-loss data.

5. Dec 29

   Conference participation

   24h Move

   -2.1%

   Announced participation and sponsorship of the 10th Annual MASH-TAG 2026 conference.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

obesity, metabolic, cardiometabolic

3 terms

obesity medical

"company's pipeline of novel obesity and metabolic therapies at the Emerging Growth"

A chronic medical condition in which a person carries excess body fat that can impair health, commonly assessed by standard measures such as body-mass index or waist circumference. For investors, obesity matters because it drives demand for medical treatments, weight-management products, health services and insurance payouts, and can affect workforce productivity and public health policy — similar to how a fleet with heavier loads needs more fuel and maintenance, creating ongoing market opportunities and costs.

metabolic medical

"pipeline of novel obesity and metabolic therapies at the Emerging Growth Conference"

Metabolic describes the chemical processes in living organisms that turn food and nutrients into energy, building materials and waste — essentially the body’s internal fuel-and-repair system. For investors, the term signals drugs, tests or devices aimed at conditions tied to those processes (such as diabetes or obesity); like improving an engine’s efficiency, successful metabolic therapies can expand a company’s market by treating widespread, chronic health problems.

cardiometabolic medical

"clinical-stage biotechnology company focused on transforming cardiometabolic diseases"

Cardiometabolic describes health conditions that affect the heart and the body’s metabolism—most commonly heart disease, high blood pressure, type 2 diabetes and obesity—that often occur together and share common causes. Investors care because these linked conditions drive large, predictable demand for drugs, medical devices and long-term care, and changes in treatment options, guidelines or costs can materially affect healthcare company revenues and government spending much like a problem in an engine and its fuel system impacts the whole vehicle.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Feb. 17, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Chief Financial Officer, will present a update highlighting the company's pipeline of novel obesity and metabolic therapies at the Emerging Growth Conference on Wednesday, February 25, 2026 at 10:15 am ET.

After the presentation, MetaVia management will open the floor for questions. Please submit your questions in advance to questions@emerginggrowth.com, or ask your questions during the event.

Please register using this link to attend the virtual conference and receive any updates that are released. To schedule a meeting with management outside of the conference, please contact Michael Miller at mmiller@rxir.com.

About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. Vanoglipel is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, vanoglipel demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects.

For more information, please visit www.metaviatx.com.

Contacts:

MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com

Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/metavia-to-highlight-novel-obesity-and-metabolic-therapies-at-upcoming-emerging-growth-conference-302688425.html

SOURCE MetaVia Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will MetaVia (MTVA) present at the Emerging Growth Conference?

MetaVia will present on Wednesday, February 25, 2026 at 10:15 am ET, giving a pipeline update. According to the company, CEO Hyung Heon Kim and CFO Marshall H. Woodworth will lead the presentation and take questions from attendees after the session.

How can investors register to attend MetaVia (MTVA) at the February 25, 2026 conference?

Investors can register using the event registration link provided by the conference to attend virtually. According to the company, registration grants access to the live presentation, any released updates, and follow-up materials distributed by the conference organizers.

Who from MetaVia (MTVA) will present the pipeline update on February 25, 2026?

The presentation will be delivered by CEO Hyung Heon Kim and CFO Marshall H. Woodworth, focusing on obesity and metabolic therapies. According to the company, both executives will provide program highlights and then open the floor for audience questions.

Can shareholders ask questions during MetaVia's (MTVA) Emerging Growth Conference presentation?

Yes, MetaVia management will take questions after the presentation and encourages advance submissions. According to the company, submit questions to questions@emerginggrowth.com or ask live during the virtual session for management to address.

How can investors schedule a one-on-one meeting with MetaVia (MTVA) management around the conference?

To schedule a meeting outside the conference, contact Michael Miller at mmiller@rxir.com to arrange a one-on-one session. According to the company, this facilitates follow-up discussions beyond the public presentation and Q&A.